Omeros (NASDAQ:OMER) Posts Earnings Results, Beats Estimates By $3.69 EPS

Omeros (NASDAQ:OMER) issued its earnings results on Tuesday. The biopharmaceutical company reported $3.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $3.69, FiscalAI reports.

Here are the key takeaways from Omeros’ conference call:

• Omeros closed an asset sale and license with Novo Nordisk for phase III-ready zaltenibart, receiving $240M upfront, $100M in near-term milestones and eligibility for up to $2.1B total plus tiered royalties, and entered a reimbursed transition services agreement to support the program.
• The FDA approved narsoplimab (commercial name YARTEMLEA) for TA‑TMA as the first and only approved therapy, with a broad label for ages ≥2, no REMS/boxed warning/vaccine requirements, and a list price of about $36,000 per vial.
• Commercial launch execution is underway — field force deployed, distributors supplied, 24‑hour delivery to hospitals, payer preauthorizations approved to date, and early formulary uptake across top transplant centers (e.g., ~50% of top 10 centers).
• Q4 2025 reported net income of $86.5M included a $237.6M gain from the zaltenibart sale; Omeros repaid its term loan and 2026 notes, ended the year with $171.8M cash/investments and only $70.8M principal of 2029 convertible notes outstanding, and expects YARTEMLEA to be self‑sustaining in 2026 with company positive cash flow in 2027.
• Early-stage pipeline progress includes the TCAT anti‑infective platform with promising animal data and patents filed, IND‑enabling work for OncotoX‑AML targeting AML, and MASP‑2/MASP‑3 small‑molecule and antibody programs — these represent meaningful long‑term upside but remain preclinical/early clinical.

Omeros Stock Performance

NASDAQ:OMER opened at $12.08 on Thursday. The company has a market capitalization of $856.47 million, a P/E ratio of -24.16 and a beta of 2.53. The stock’s 50 day moving average price is $11.40 and its 200 day moving average price is $9.78. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65.

Insider Transactions at Omeros

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 12.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in Omeros by 26.8% in the 4th quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock worth $2,658,000 after purchasing an additional 32,707 shares during the last quarter. Corient Private Wealth LLC grew its holdings in Omeros by 12.9% during the fourth quarter. Corient Private Wealth LLC now owns 687,325 shares of the biopharmaceutical company’s stock valued at $11,805,000 after purchasing an additional 78,563 shares during the last quarter. Virtus Investment Advisers LLC acquired a new position in Omeros during the fourth quarter valued at approximately $450,000. Wellington Management Group LLP raised its position in shares of Omeros by 4.2% in the fourth quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock valued at $3,480,000 after purchasing an additional 8,170 shares during the period. Finally, Millennium Management LLC raised its position in shares of Omeros by 10.0% in the fourth quarter. Millennium Management LLC now owns 441,811 shares of the biopharmaceutical company’s stock valued at $7,588,000 after purchasing an additional 39,997 shares during the period. 48.79% of the stock is owned by institutional investors.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 beat and return to profitability — Omeros reported Q4 net income of $86.5M ($1.22/sh) and EPS of $3.14, well above expectations, providing an immediate earnings catalyst and improving near‑term financial visibility. Business Wire: Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
• Positive Sentiment: Novo Nordisk deal windfall cited as a boost — Media coverage highlights a one‑time windfall from a Novo Nordisk arrangement that materially lifted Q4 results and investor sentiment around non‑recurring revenue. MSN: Omeros rises as Novo deal boosts Q4 earnings
• Positive Sentiment: Commercial product outlook — Management said YARTEMLEA is expected to be financially self‑sustaining in 2026 and the company targets positive cash flow in 2027, which reduces financing risk and supports a higher valuation multiple if execution holds. Seeking Alpha: Omeros expects YARTEMLEA to be financially self-sustaining in 2026
• Positive Sentiment: Unusual options activity — Large call buying (≈7,487 calls) signals bullish positioning by traders ahead of or after the earnings news, which can amplify short‑term upside and volatility. Options activity report
• Neutral Sentiment: Earnings call and transcripts published — Full conference call transcript and replay are available for investors who want management color on revenue composition and deal details; useful for due diligence but not an immediate market mover on its own. Insidermonkey: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Analyst outlook still points to negative FY EPS — Despite the quarter’s one‑off gains, consensus models still forecast a negative EPS for the fiscal year, leaving longer‑term valuation dependent on successful commercialization and recurring revenue ramp. MarketBeat: OMER analyst data

Analyst Upgrades and Downgrades

OMER has been the topic of several research reports. HC Wainwright upped their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday, January 27th. Finally, Wall Street Zen downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and an average price target of $40.33.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.